Abstract
8085 Background: Poziotinib is an oral irreversible inhibitor of EGFR, HER2 and HER4, and has shown preclinical activity in lung cancer models with EGFR mutations including T790M. This phase II stu...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
